Ausdal Financial Partners Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 17.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,640 shares of the biopharmaceutical company’s stock after purchasing an additional 3,587 shares during the period. Ausdal Financial Partners Inc.’s holdings in Pfizer were worth $894,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Texas Yale Capital Corp. raised its position in shares of Pfizer by 1.5% during the 2nd quarter. Texas Yale Capital Corp. now owns 83,436 shares of the biopharmaceutical company’s stock valued at $3,027,000 after buying an additional 1,255 shares in the last quarter. Ken Stern & Associates Inc. raised its position in Pfizer by 7.2% in the 2nd quarter. Ken Stern & Associates Inc. now owns 18,906 shares of the biopharmaceutical company’s stock worth $686,000 after purchasing an additional 1,266 shares during the period. Abbrea Capital LLC raised its position in Pfizer by 2.0% in the 2nd quarter. Abbrea Capital LLC now owns 64,420 shares of the biopharmaceutical company’s stock worth $2,337,000 after purchasing an additional 1,274 shares during the period. American Asset Management Inc. raised its position in Pfizer by 4.7% in the 2nd quarter. American Asset Management Inc. now owns 28,631 shares of the biopharmaceutical company’s stock worth $1,039,000 after purchasing an additional 1,279 shares during the period. Finally, Private Wealth Advisors Inc. raised its position in Pfizer by 6.7% in the 2nd quarter. Private Wealth Advisors Inc. now owns 20,600 shares of the biopharmaceutical company’s stock worth $747,000 after purchasing an additional 1,285 shares during the period. 68.96% of the stock is owned by institutional investors and hedge funds.
Shares of PFE stock opened at $43.52 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. The stock has a market capitalization of $255.56 billion, a price-to-earnings ratio of 16.42, a P/E/G ratio of 2.16 and a beta of 0.88. Pfizer Inc. has a one year low of $33.20 and a one year high of $45.81.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. The business had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 EPS. On average, equities analysts forecast that Pfizer Inc. will post 3 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be paid a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a yield of 3.13%. Pfizer’s dividend payout ratio is currently 51.32%.
In other Pfizer news, major shareholder Pfizer Inc acquired 55,556 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the purchase, the insider now owns 21,976,484 shares in the company, valued at $395,576,712. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now owns 72,672 shares in the company, valued at $2,979,552. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.
A number of analysts recently weighed in on the stock. Cantor Fitzgerald set a $45.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 27th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, July 31st. Goldman Sachs Group reissued a “neutral” rating and issued a $42.00 price objective on shares of Pfizer in a research report on Wednesday, August 1st. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Finally, Deutsche Bank set a $45.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 21st. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have given a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $42.95.
COPYRIGHT VIOLATION WARNING: “Ausdal Financial Partners Inc. Grows Holdings in Pfizer Inc. (PFE)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/06/ausdal-financial-partners-inc-grows-holdings-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Further Reading: Hedge Funds Explained
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.